In vitro-in vivo correlation on delivery of drug candidates to articular cartilage

Pharmaceutical Research

Volumn 25, Issue 7, 2008, Pages 1641-1646

  Wang, Qin ^a,b   Glasson, Sonya ^a   Raut, Uma ^a   Emerson, Jamie ^a   Blanchet, Tracey ^a   Bridson, Gary ^a   Sheldon, Richard ^a   Mollova, Nevena ^a,c   Morris, Elisabeth ^a   Xu, Xin ^a   Patel, Vikram S ^a  

^a PFIZER INC   (United States)

^b BIOGEN   (United States)

^c CV THERAPEUTICS INC   (United States)

Author keywords

Cartilage; Drug delivery; In vitro in vivo correlation; Synovial

Indexed keywords

BIPHENYL SULFONAMIDE CARBOXYLIC ACID; CARBOXYLIC ACID DERIVATIVE; SERUM ALBUMIN;

ANIMAL EXPERIMENT; ARTICLE; ARTICULAR CARTILAGE; CARTILAGE; CARTILAGE CELL; COW; CULTURE MEDIUM; DRUG DELIVERY SYSTEM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; IN VIVO STUDY; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; NONHUMAN; PRIORITY JOURNAL; RABBIT; SYNOVIAL FLUID;

ANIMALS; AREA UNDER CURVE; BLOOD PROTEINS; CARTILAGE, ARTICULAR; CATTLE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; ENZYME INHIBITORS; EXCIPIENTS; INJECTIONS, INTRA-ARTERIAL; JOINTS; MALE; MASS SPECTROMETRY; MATRIX METALLOPROTEINASE 13; PROTEIN BINDING; RABBITS; SERUM ALBUMIN; SYNOVIAL FLUID;

EID: 44749090456     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-008-9557-8     Document Type: Article

References (31)

1. J.M. Milner, and T.E. Cawston. Matrix metalloproteinase knockout studies and the potential use of matrix metalloproteinase inhibitors in the rheumatic diseases. Curr. Drug Targets Inflamm. Allergy. 4(3):363-375 (2005).
2. J. Martel-Pelletier, D.J. Welsch, and J-P. Pelletier. Metalloproteases and inhibitors in arthritic diseases. Best Pract. Res. Clin. Rheumatol. 15(5):805-829 (2001).
3. S.S. Glasson, R. Askew, B. Sheppard, B. Carito, T. Blanchet, H-L. Ma, C.R. Flannery, D. Peluso, K. Kanki, Z. Yang, M.K. Majumdar, and E.A. Morris. Deletion of active ADAMTS5 prevents cartilage degradation in a murine model of osteoarthritis. Nature. 434:644-648 (2005).
4. H. Nagase, and M. Kashiwagi. Aggrecanases and cartilage matrix degradation. Arthritis Res. Ther. 5(2):94-103 (2003).
5. J.W. Skiles, N.C. Gonnella, and A.Y. Jeng. The design, structure, and clinical update of small molecular weight matrix metalloproteinase inhibitors. Curr Med Chem. 11(22):2911-2977 (2004).
6. M. Sabatini, C. Lesur, M. Thomas, A. Chomel, P. Anract, G. de Nanteuil, and P. Pastoureau. Effect of inhibition of matrix metalloproteinases on cartilage loss in vitro and in a guinea pig model of osteoarthritis. Arthritis Rheum. 52(1):171-180 (2005).
7. T.G. Benedek. A history of the understanding of cartilage. OsteoArthr. Cartil. 14:203-209 (2006).
8. H. Imhof, M. Breitnseher, F. Kainberger, and S. Trattnig. Degenerative joint disease: cartilage or vascular disease? Skelet. Radiol. 26:398-403 (1997).
9. J.E. Shea, and S.C. Miller. Skeletal function and structure: implication of tissue-targeted therapeutics. Adv. Drug Deliv. Rev. 57:945-957 (2005).
10. J. Li, T.S. Rush III, W. Li, D. DeVincentis, X. Du, Y. Hu, J.R. Thomason, J.S. Xiang, J.S. Skotnicki, and S. Tam. Synthesis and SAR of highly selective MMP-13 inhibitors. Bioorg. Med. Chem. Lett. 15:4961-4966 (2005).
11. Y. Hu, J. Xiang, M. DiGrandi, X. Du, M. Ipek, L. Laakso, J. Li, W. Li, T. Rush, J. Schmid, J. Skotnicki, S. Tam, J. Thomason, Q. Wang, and J. Levin. Potent, selective and orally bioavailable matrix metalloproteinase-13 inhibitors for the treatment of osteoarthritis. Bioorg. Med. Chem. 13:6629-6644 (2005).
12. R.A. Gatter, and H.R. Schumacher. A practical handbook of joint fluid analysis, 2nd edition. Lea & Febiger, Philadelphia, 1991, pp. 70-77.
13. D.J. McCarty. The physiology of normal synovium. In L. Sokoloff (ed.), The Joints and Synovial Fluid, Vol. II, Chapter 7, Academic, New York, 1980, pp. 294-315.
14. P.S. MacWilliams, and K.R. Friedrichs. Laboratory evaluation and interpretation of synovial fluid. Vet. Clin. Small. Anim. 33:153-178 (2003).
15. B. Davis, and T. Morris. Physiological parameters in laboratory animals and humans. Pharm. Res. 10:1093-1096 (1993).
16. P.A. Simkin, M.P. Wu, and D.M. Foster. Articular pharmacokinetics of protein-bound anti-rheumatic agents. Clin. Pharmacokinet. 25:342-50 (1993).
17. W.F. Elmquist, K.K.H. Chan, and R.J. Sawchuck. Transsynovial drug distribution: synovial mean transit time of diclofenac and other nonsteroidal anti-inflammatory drugs. Pharm. Res. 11:1689-1697 (1994).
18. S.G. Owen, H.W. Francis, and M.S. Roberts. Disappearance kinetics of solutes from synovial fluid after intra-articular injection. Br. J. Clin. Pharmacol. 38:349-355 (1994).
19. P. Netter, B. Bannwarth, and M-J. Rojer-Morrot. Recent finding on the pharmacokinetics of non-steriodal anti-inflammatory drugs in synovial fluid. Clin. Pharmacokinet. 17(3):145-162 (1989).
20. R.O. Day, A.J. McLachlan, G.G. Graham, and K.M. Williams. Pharmacokinetics of nonsteroidal anti-inflammatory drugs in synovial fluid. Clin Pharmacokinet. 36(3):191-210 (1999).
21. F. Lapicque, P. Vergne, J.Y. Jouzeau, D. Loeuille, P. Gillet, E. Vignon, P. Thomas, P. Velicitat, D. Turck, C. Guillaume, A. Gaucher, P. Bertin, and P. Netter. Articular diffusion of meloxicam after a single oral dose: relationship to cyclo-oxygenase inhibition in synovial cells. Clin. Pharmacokinet. 39(5):369-82 (2000).
22. O.G. Nilsen. Clinical pharmacokinetics of tenoxicam. Clin. Pharmacokinet. 24:16-43 (1994).
23. S.X. Peng, E.C. von Bargen, D.M. Bornes, and S. Pikul. Permeability of articular cartilage to matrix metalloprotease inhibitors. Pharm. Res. 15:1414-1418 (1998).
24. R.C. Evens, and T.M. Quinn. Solute diffusivity correlates with mechanical properties and matrix density of compressed articular cartilage. Arch. Biochem. biophys. 442:1-10 (2005).
25. J.H. Kimura. The role of water, proteoglycan, and collagen in solute transport in cartilage. In K.E. Kuettner (ed.), Articular Cartilage and Osteoarthritis, Raven, New York, 1991, pp. 355-372.
26. A.M. Garcia, E.H. Frank, P.E. Grimshaw, and A.J. Grodzinsky. Contributions of fluid convection and electrical migration to transport in cartilage: relevance to loading. Arch. Biochem. Biophys. 333:317-325 (1996).
27. F. Eckstein, M. Tieschky, S.C. Faber, M. Haubner, H. Kolem, K-H. Endlmeier, and M. Reiser. Effect of physical exercise on cartilage volume and thickness in vivo: MR imaging study. Radiology. 207:243-248 (1998).
28. U.G. Kersting, J.J. Stubendorff, M.C. Schmidt, and G-P. Bruggemann. Changes in knee cartilage volume and serum COMP concentration after running exercise. Osteoarthr. Cartil. 13:925-934 (2005).
29. M. Kurowski, and A. Dunky. Transsynovial kinetics of piroxicam in patients with rheumatoid arthritis. Eur. J. Clin. Pharmacol. 34:401-406 (1998).
30. J.B. Whitiam, K.F. Brown, M.J. Crooks, and G.F.W. Room. Transsynovial distribution of ibuprofen in arthritis patients. Clin. Pharmacol. Ther. 29:487-492 (1981).
31. R.O. Day, H. Francis, J. Vial, G. Geisslinger, and K.M. Williams. Naproxen concentrations in plasma and synovial fluid and effects on prostanoid concentrations. J. Rheumatol. 22(12):2295-30 (1995).